Medwin's Pharmacy

Phone: (989) 755-7998

Hepatitis C Enrollment Form

Fax Referral to: (989) 755-7993 PRESCRIBER INFORMATION PATIENT INFORMATION Please fax copy of patient's insurance card including both sides Prescriber's Name ___ ____Last Four of SS# ______ Gender ___ DOB _ Group/Hospital ___ __ Height _____ _ Phone __ City, State, ZIP _____ Address __ City, State, ZIP ____ ___ Fax _ Language Preference: English Spanish Other ___ Contact Person __ Phone INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides) Prior Authorization Reference number MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed) B18.2 Chronic Hepatitis C K72.90 Hepatic failure, unspecified without coma C22.0 Liver Cell Carcinoma Other Diagnosis: ICD-10 Code ____ ____ Description _ HIV Coinfected: Yes No Viral Load ____ _____IU/ml Viral Load Date _____ HBV Coinfected: Yes No Previous therapy history: Naïve _____ Relapsed ___ Partial Responder ____ _ Null _ Date(s) of previous therapy and meds ___ Cirrhosis: Yes No Compensated OR Decompensated Fibrosis Score _ Liver Transplant: Yes No Waiting for Liver Transplant: Yes No Please include hard copies of: genotype, viral load, liver biopsy scans, CBC, CMP, HIV, PT/INR, H&P, NS5A resistance testing and pertinent office visit notes. PRESCRIPTION INFORMATION DAKLINZA® (daclatasvir) ☐ 30mg ☐ 60mg Disp. 28 Sig: One tablet daily with or without food. Total duration of therapy Weeks **TECHNIVIE™** Sig: Take 2 tablets once daily (in am) with food. Refill: x ____ Disp. 28 day supply Total duration of therapy _ Weeks Disp. 28 day supply Sig: Take once daily with food Refill: x __ Total duration of therapy _ ZEPATIER (elbasvir 50mg/grazoprevir 100mg) disp. 28 Refill: x ___ __ duration of therapy ____ Weeks Sig: Take 1 tablet daily with or without food. ☐ NS5A resistance testing included RIBAVIRIN 200mg: RIBAPAK (28 day supply): MODERIBA (28 day supply): ☐ 1200mg daily/600mg QAM—600mg QPM ☐ 1200mg daily/600mg QAM—600mg QPM Directions _ 1000mg daily/600mg QAM—400mg QPM 1000mg daily/600mg QAM—400mg QPM Quantity___ 800mg daily/400mg QAM—400mg QPM < 75kg = 1000mg/day</p> 600mg daily/200mg QAM-400mg QPM 600mg daily/200mg QAM-400mg QPM ≥ 75kg = 1200mg/day Total duration of therapy _ . Weeks Refill: x ___ Total duration of therapy _ SOVALDI™ (sofosbuvir) 400mg disp. 28 Sig: 400mg daily Refill: x ___ Total duration of therapy _ EPCLUSA (sofosbuvir 400mg/velpatasvir 100mg) disp. 28 Sig: 1 tablet daily Refill: x _ __ Total duration of therapy ___ ☐ VIEKIRA XR disp. 84 tabs (28 day supply) Sig: Take 3 tablets by mouth once daily. __ duration of therapy ___ Weeks _ duration of therapy _ Refill: x ____ ☐ VIEKIRA PAK disp. 28 day supply. Sig: Take 2 ombitasvir, paritaprevir, ritonavir 12.5mg/75mg/50mg tablets once daily (in am) and 1 dasabuvir 250mg tablet twice daily (am & pm) with a meal. HARVONI® (ledipasvir 90mg/sofosbuvir 400mg) disp. 28 Sig: 1 tablet daily Refill: x _ Total duration of therapy _ MAVYRET™ (glecaprevir 100mg/pibrentasvir 40mg) disp 84 Refill: x __ Total duration of therapy __ Weeks Sig: Take 3 tablets (contents of one daily dose card) by mouth once daily with food. Supportive Therapy: PROMACTA* PO QD 12.5mg tablets 25mg tablets 50mg tablets ___ Total duration of therapy _____ Weeks Quantity_ Refill: x *Titrate based on platelet count not to exceed 100mg PO QD *Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network. Office ALL fills Other _ Ship to: Patient Office First Fill _ Date ___ (future fills to Patient) Product Substitution permitted Dispense as Written Prescriber's Supervising physician Signature Date . Date

CONFIDENTIALITY STATEMENT. This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law if the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.